Bayer's Stock Climbs Above Key Moving Average as Legal Hurdles and Cash Flow Strains Collide

Bayer shares gain 5% after judge blocks $7.25B Roundup settlement; Supreme Court ruling, US pricing probe, and cash flow risks loom.

The legal saga weighing on Bayer took an unexpected turn last week when a US judge blocked a proposed $7.25 billion settlement over glyphosate claims. While the ruling might sound like a setback, the market read it differently: shares of the Leverkusen-based group closed Friday at €37.81, up 2.13% on the day and nearly 5% higher on the week.

That gain pushed the stock just above its 50-day moving average at €37.80 — a level chart watchers view as a short-term buy signal. The 200-day line, last crossed to the upside on June 17, now offers support at €36.22, while resistance sits at €39.69. Since hitting a 52-week low of €25.09, the shares have recovered more than 50%, though they remain roughly 24% below the year's high of €49.93.

Behind the price action lies a far more complex picture. The rejected settlement in Missouri — which management in Leverkusen sees as an opportunity to renegotiate the procedural framework for thousands of Roundup lawsuits — shifts attention to the US Supreme Court. A landmark ruling expected at the end of June will determine whether federal law preempts state-level requirements on product warning labels. The outcome will massively shape Bayer's future liability exposure.

Meanwhile, a fresh political threat emerged: the US government launched an official investigation into Germany's drug pricing policies, accusing Berlin of under-reimbursing medicines and forcing American patients to shoulder a disproportionate share of global R&D costs. Bayer, which generates a large chunk of its revenue in the pharma segment, could face punitive tariffs. Rivals such as Roche have already struck separate agreements with Washington.

A Biotech Buy and a Pharma Fight

Amid the legal noise, Bayer quietly closed the acquisition of Perfuse Therapeutics for an upfront payment of $300 million, with milestone payments that could lift the total consideration to $2.45 billion. The deal's centrepiece is PER-001, an intravitreal implant targeting glaucoma and diabetic retinopathy that is currently in Phase II trials. Bayer will fold the asset into its existing ophthalmology portfolio.

In oncology, a separate courtroom battle is intensifying. Bayer sued Johnson & Johnson in February, alleging that J&J's competing prostate cancer drug Erleada uses a flawed real-world analysis to claim superiority over Bayer's Nubeqa. A federal judge in Manhattan declined to block those claims, so on June 15 Bayer filed an amended complaint seeking a permanent injunction plus damages. The stakes are meaningful: Nubeqa generated roughly $1.92 billion in revenue in the first nine months of 2025, while Erleada pulled in $2.62 billion over the same period.

Cash Flow Under Siege

Pipeline acquisitions and litigation come at a cost. Management expects a cash outflow of around €5 billion in 2026 just for ongoing legal proceedings. That could push free cash flow to as low as minus €2.5 billion, while net financial debt may swell to €33 billion by year-end. To counter the pressure, Bayer is banking on higher earnings from its agricultural and consumer health divisions.

Later this month, a new €275 million production facility in Leverkusen — which uses artificial intelligence and sharply reduces CO? emissions — won an industry award, offering a bright spot for operational progress.

Analysts remain split. UBS continues to recommend buying the stock, while Jefferies has a "Hold" rating until the financial burden of the Monsanto legacy becomes clearer. The next hard data point arrives on July 9, when a hearing in Missouri will provide fresh insight into the litigation landscape.